医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Clot Management Device Market in Brazil, Russia, India and China to Grow at Robust Annual Rate of Nearly 12 Percent Through 2017

2012年11月15日 PM10:25
このエントリーをはてなブックマークに追加


 

TORONTO

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the market for clot management devices in Brazil, Russia, India and China (BRIC) will expand at a robust rate averaging 11.7 percent per year through 2017. The most significant growth will be in percutaneous thrombectomy devices and neurovascular embolectomy devices.

The growth of these emerging markets will be driven by growing clinical evidence and an increasing number of physicians trained in percutaneous techniques, as well as rising prevalence of peripheral artery disease, coronary heart disease and kidney diseases that require more clot management interventions.

In all of these countries, percutaneous thrombectomy is a relatively new procedure to physicians who now rely on systemic thrombolysis and vascular surgeries as the preferred treatment options. Emergence of clinical data demonstrating that percutaneous thrombectomy devices offer improved outcomes, reduce procedure times and treatment complications and expand treatable populations will increase uptake of the newer devices. As a result, the BRIC market for percutaneous thrombectomy devices, which include mechanical thrombectomy, aspiration thrombectomy and pharmacomechanical thrombectomy devices, will grow at an average annual rate of nearly 20 percent through 2017.

The BRIC market for neurovascular embolectomy devices will see significant technological innovation. Second-generation stent-based neurovascular embolectomy devices such as Stryker’s Trevo Pro and Covidien’s Solitaire FR will enter the markets in these countries by 2013. This market will grow at an average annual rate of over 20 percent through 2017.

“The main limiter in these countries is the lack of reimbursement for premium-priced technologies,” said MRG Analyst Tony Su. “Health insurance systems in these countries are relatively underdeveloped, and manufacturers face difficulties in obtaining approval for coverage with private health insurance companies. The main task for manufacturers is to collect clinical data demonstrating the clinical superiority of these more-expensive devices over those used in standard treatments to gain favorable reimbursement.”

Millennium Research Group’s BRIC Markets for Clot Management Devices 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters for percutaneous thrombectomy devices (which include mechanical thrombectomy devices, aspiration thrombectomy devices, and pharmacomechanical thrombectomy (PMT) devices), embolectomy balloon catheters, catheter-directed thrombolysis (CDT) devices, IVCFs, and neurovascular embolectomy devices in Brazil, Russia, India and China.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

CONTACT

Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
or
Millennium
Research Group
Alex Jablokow, 617-599-8613
ajablokow@mrg.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.